AFM-Telethon, one of IRDiRC members, and the investment fund “SPI – Agencies Industrial Projects”, managed by Bpifrance, join forces with the aim of creating Europe’s largest development center for the production of gene and cell therapies. This project aims both to create an industrial-scale production platform and to carry to completion the development of gene and cell therapies. This new center, which will have a projected area of 13,000 m², represent the key elements of an industrial sector that will meet the needs of many current AFM-Telethon laboratories and those of numerous academic and biotech industry actors by offering a platform for the production of their therapies, whether they are for clinical trials or post-marketing diffusion.
As such, it will reinforce the efforts of the AFM-Telethon for providing therapeutic solutions for rare and common diseases patients, being able to ensure the large-scale production of drugs and bring them to commercialization. AFM-Telethon will have a majority share in the company that has the capital required to launch its production plant and the development of innovative bio-therapeutics. The investment of AFM-Telethon’s partner, SPI, will allow for the acceleration of industrialization of the required technology.
For the full press message (in French), click here.